Diabetes meds vary in safety and effectiveness, study shows

March 31, 2016

(HealthDay)—A study of nearly a half-million people with type 2 diabetes shows there are pros and cons to nearly every form of drug therapy for the disease.

In the British study, researchers looked at patient outcomes from a large U.K. database of almost 470,000 adults with type 2 diabetes, tracked between 2007 and 2015.

Julia Hippisley-Cox and Carol Coupland, of the University of Nottingham, sought to parse out differences among a variety of . They accounted for complicating patient factors such as age, sex, smoking and poverty, as well as how long a person had been diagnosed with type 2 diabetes.

The researchers also focused on five major outcomes linked to diabetes: blindness, amputation, severe kidney failure, and high or low .

Reporting March 30 in BMJ, they found that when a class of drugs called glitazones (Actos, Avandia) was prescribed along with the standard diabetes drug metformin, there was a higher risk for kidney failure than with metformin alone.

The same was true when another class of meds called gliptins (Januvia, Onglyza and others) was combined with metformin.

However, there were "up" sides to these drug combos as well. People who took a gliptin or a glitazone plus metformin had "significantly lower" risks for than those who took metformin alone, the research found.

Finally, the study looked at "triple" therapy: patients taking metformin, a gliptin or a glitazone, and a sulphonylurea, another type of diabetes drug. This combination was linked to "significantly higher" odds for episodes of potentially dangerous , the British researchers said, compared to people taking metformin alone.

On the other hand, triple-therapy users had a reduced risk for diabetes-linked blindness, compared to the metformin-only group.

The study doesn't establish direct cause-and-effect relationships between the various drugs and these outcomes. Still, according to experts, the findings support the notion that is never a "one-size-fits-all" endeavor.

"There are many treatment options for diabetes—they have the benefit of lowering , but they also carry risk," said Dr. Robert Courgi, an endocrinologist at Northwell Health's Southside Hospital in Bay Shore, N.Y.

He said that standard guidelines typically list metformin as a first-line therapy against type 2 disease, but additional drugs may be needed. "Ultimately, the physician and the patient need to work together to find the best treatment possible," Courgi said.

Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City. He believes the field of diabetes care is constantly evolving.

"Treating type 2 diabetes used to be like a singles pingpong game—give a pill, lower blood sugar," he said.

However, "over the last 75 years or so we have learned that it is more of a team effort, because the process of safely lowering blood sugar is more complicated than previously thought," Bernstein explained. "The goal of treatment for all is to prevent complications and have a high quality of life."

Different medications have different targets and effects, he said, and "the art of treatment today mixes and matches these medications depending on age, weight, activity."

Explore further: Study confirms link between diabetes drug and increased risk of bladder cancer

More information: For more on the treatment of type 2 diabetes, head to the American Diabetes Association.

Related Stories

Study confirms link between diabetes drug and increased risk of bladder cancer

March 31, 2016
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer, finds a study published by The BMJ today. The findings suggest that the risk increases with increasing duration of use and dose.

Ranolazine added to glimepiride cuts HbA1c in T2DM

January 18, 2016
(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published ...

Popular diabetes drug may be safe for patients with kidney disease

December 23, 2014
The most popular treatment for type 2 diabetes, metformin, may be safer for patients with mild to moderate kidney disease than guidelines suggest, according to a new, systematic review of the literature published by Yale ...

Metformin beats other type 2 diabetes drugs for first treatment: study

October 28, 2014
(HealthDay)—People newly diagnosed with type 2 diabetes who are initially given the drug metformin are less likely to eventually need other drugs to control their blood sugar, a new study suggests.

Common diabetes drugs may carry risk, study suggests

September 26, 2013
(HealthDay)—Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says.

Diabetes drug metformin's primary effect is in the gut, not the bloodstream

August 18, 2015
Although metformin was introduced as a treatment for type 2 diabetes nearly 60 years ago and is now the recommended first-line treatment for newly diagnosed patients, researchers still debate precisely how the drug works. ...

Recommended for you

Controlling diabetes with your phone might be possible someday

November 21, 2017
Think about this. You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels ...

Insulin pill may delay type 1 diabetes in some

November 21, 2017
(HealthDay)—It's often said that timing is everything. New research suggests this may be true when giving an insulin pill to try to prevent or delay type 1 diabetes.

Simple test predicts diabetes remission following weight loss surgery

November 21, 2017
A new simple test that helps predicts which people with type 2 diabetes will benefit most from weight loss surgery has been developed by a UCL-led team.

Pre-diabetes discovery marks step towards precision medicine

November 20, 2017
Researchers from the University of Sydney's Charles Perkins Centre have identified three specific molecules that accurately indicate insulin resistance, or pre-diabetes - a major predictor of metabolic syndrome, the collection ...

Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017
Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) ...

Pregnancy-related conditions taken together leave moms—and dads—at risk

November 14, 2017
Research has already shown that women who develop either diabetes or high blood pressure during pregnancy are at risk of getting type 2 diabetes, high blood pressure or heart disease years later. Now, a new study from a team ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.